BioSig Technologies Invests in Union College’s Internship Program
November 07 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “The
Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company’s founder, Chairman &
CEO Kenneth L. Londoner is making a gift to New York-based Union
College in order to support the school’s growing internship
program.
Last summer, a handful of Union students joined BioSig’s
internship program, a highly immersive internship experience, which
gives students an opportunity to enhance their professional
interests in an entrepreneurial environment. During their summers
at BioSig, students work on numerous advanced projects. These range
from researching novel therapies and clinical study breakthroughs,
to preparing business plans and corporate presentations, to
analyzing international healthcare landscapes and policy standards.
To address the ongoing student debt crisis, interns get paid to
offset their living expenses and tuition fees. Union College will
use the funds to support internships through its Becker Career
Center. In 2018-19, 524 employers recruited Union students for
1,573 internship opportunities. This includes opportunities through
the summer community internships and admissions scholars’
internships programs, as well as Making U Possible: The
Presidential Initiative for Scholarship and Immersive Excellence.
Created last fall, the initiative ensures that talented students
from all backgrounds not only can afford a Union education but also
are able to take full advantage of opportunities in and out of the
classroom, including internships.
“We are grateful to BioSig Technologies and its founder and CEO,
Kenneth Londoner, for this extraordinary gift,” said Union
President David R. Harris. “One of the distinguishing
characteristics of a liberal arts education at Union is our
emphasis on applying ideas through practical experience. Thanks to
the generosity and philanthropy of BioSig Technologies, we will be
able to significantly increase internship opportunities and create
new experiences for our students.”
“Our small Company hosted over 50 very talented students over
the past five years. We feel that it is our duty to help future
generations launch their careers, ultimately allowing them to
contribute to society by creating meaningful jobs and introducing
impactful solutions. We received over 250 applications for eight
internship positions in 2019, and we are committed to growing our
internship program to connect more students with exciting
opportunities. We look forward to collaborating with Union College
on this wonderful initiative,” commented Kenneth L. Londoner,
Chairman and CEO of BioSig Technologies, Inc.
About Union College Founded in 1795 in
Schenectady, N.Y., Union College is a leading residential liberal
arts college focused exclusively on undergraduates. Union
provides a rigorous, holistic and immersive education that
emphasizes integration, innovation, inclusion and reflection for
every student. The Union curriculum emphasizes collaboration
with students and faculty through small classes, undergraduate
research, interdisciplinary and international study, and
community-based experiences.
About BioSig Technologies BioSig Technologies
is a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP(tm) System.
The technology has been developed to address an unmet need in a
large and growing market.
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory. The system is indicated for use under the supervision
of licensed healthcare practitioners who are responsible for
interpreting the data. This novel cardiac signal acquisition and
display system is engineered to assist electrophysiologists in
clinical decision-making during electrophysiology procedures in
patients with abnormal heart rates and rhythms. BioSig’s ultimate
goal is to deliver technology to improve upon catheter ablation
treatments for the prevalent and potentially deadly arrhythmias,
Atrial Fibrillation and Ventricular Tachycardia. BioSig has
partnered with Minnetronix on technology development and received
FDA 510(k) clearance for the PURE EP(tm) System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024